The Central Drugs Standard Control Organization (CDSCO) has released new draft guidelines for Medical Device Software, marking a crucial step to align India’s regulatory framework with global standards. This initiative aims to provide manufacturers and importers with greater clarity on regulatory aspects within the country.
The Drugs Controller General of India (DCGI) announced the preparation of this draft, emphasizing its role in harmonizing requirements with globally accepted practices. Accordingly, the 76-page document details the scope, definitions, classification, and applicable standards. It also outlines requirements for technical documents, quality management systems, and licensing authorities.
Key Features of the Medical Device Software Guidance
This extensive guidance covers various types of medical device software, outlining specific considerations for clinical investigations and performance evaluations. Importantly, it includes provisions for software used in in vitro diagnostics (IVDs). Manufacturers, therefore, need to review these detailed requirements to ensure full compliance.
Industry Feedback on Medical Device Software Regulations
The Medical Technology Association of India (MTaI), representing multinational corporations, generally welcomed the draft. However, MTaI urged CDSCO to provide greater clarity on several key areas. They specifically seek refined clinical evaluation protocols and improved algorithm change management, particularly for AI/ML-based medical devices. Additionally, MTaI advocates for streamlining compliance requirements for low-risk Software as a Medical Device (SaMDs) to ensure regulatory proportionality and ease of implementation.
Broader Context for Medical Device Software
The Medical Devices Rules of 2017 currently outline technical and quality standards for both Software in a Medical Device (SiMD) and Software as a Medical Device (SaMD). These regulations assess the safety, performance, and quality of medical device software, helping applicants meet necessary requirements for manufacturing, marketing, and distribution licenses across India. This proactive step by CDSCO reflects a commitment to keeping pace with the rapidly evolving digital health landscape, thereby fostering safe, innovative, and globally competitive MedTech software solutions from India. For those looking to deepen their expertise in this area, exploring courses related to medical device regulations and compliance could be highly beneficial.
Frequently Asked Questions
Q1: What is the main purpose of the new CDSCO draft guidelines?
The main purpose is to align India’s regulatory framework for medical device software with global standards, bringing more clarity on regulatory aspects for manufacturing or importing these devices in the country.
Q2: What specific concerns did MTaI raise regarding the draft guidelines?
MTaI requested greater clarity on clinical evaluation protocols and algorithm change management, especially for AI/ML-based medical devices. They also suggested streamlining compliance for low-risk Software as a Medical Device (SaMDs).
Q3: Are the new guidelines open for public feedback?
Yes, the draft guidelines are open for public comments, with a 30-day period provided for submissions from stakeholders.
References
- CDSCO brings updated guidance on med device software; Lobby seeks clarity onAI-ML devices’ evaluation protocols – ETHealthworld
- MTaI welcomes CDSCO’s Draft Guidance on Medical Device Software. MTaI. (2025, October 22).
- Regulatory Updates: Key Changes in India’s Medical Device Standards (2025–2026). Astute Labs. (2025, April 9).
- India’s Medical Device Regulations: A 2025 Update. Pacific Bridge Medical. (2025, August 12).
- AI Medical Device Compliance in India. Prospect Legal.
- Pathways for AI-Enabled Healthcare Reform. Drishti IAS. (2025, October 17).
- CDSCO Guidelines for Medical Devices in India – Overview. Register Karo. (2025, October 17).
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.